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ABSTRACT
Nicotine, the active compound in cigarettes, was considered as the risk factor for type 2 diabetes 
mellitus (T2DM). In the human body, nicotine would be metabolized by the enzyme cytochrome 
P450 2A6 (CYP2A6). CYP2A6 was known to be highly polymorphic. The active form of this 
gene was CYP2A6 *1, while the CYP2A6 *4 and CYP2A *9 alleles were the inactive alleles. The 
presence of this inactive allele caused the decreased activity of CYP2A6 so that it would affect the 
level of nicotine in the blood and would eventually cause an increased blood sugar levels. This 
study aimed to determine the effect of CYP2A6 polymorphism on glycohemoglobine levels among 
Javanese smokers. The blood sugar levels were measured by hemoglobin A1c (HbA1c). In this study, 
33 active smokers involved in the study were identified as slow metabolizers, by which 63.9% of all 
test participants had CYP2A6 *1/*4 genotype and as many as 6.1% of the test participants had the 
CYP2A6 *1/*4/*9. The HbA1c levels among the participants have been analyzed, 28 participants 
were in normal range (4.83-5.56%); 4 participants were identified in prediabetes condition (5.70% 
- 5.97%) and 1 participant was in diabetes with HbA1c level was 7.16%. This condition indicates 
that the presence of CYP2A6 *4 and *9 alleles will affect HbA1c levels which can eventually lead 
to T2DM disease.
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INTRODUCTION
Diabetes, one of the underdiagnosed diseases, has been 
a serious threat to public health. The uncontrolled blood 
sugar could have been associated with cardiovascular 
diseases and blood pressure, development of renal 
(kidney) complications, nephropathy, retinopathy and 
foot ulcer. In some cases, by the time diabetes was 
diagnosed, the complications of diabetes might already 
be present (Buell et al., 2007). IDF Diabetes Atlas 8th 
Edition (International Diabetes Federation, 2017) was 
estimated that 82 million adults aged 20-79 years were 
living with diabetes in the South East Asia Region in 
2017, representing a regional prevalence of 8.5%. About 
45.8% of these diabetes cases were undiagnosed. 
As of 2017, Indonesia was the world’s top ten countries 
suffering from diabetes including China, India, United 
State, Brazil and Mexico. Approximately, 10 million 
people had diabetes in this country (International 
Diabetes Federation, 2017).  Close to half (48.8%) of 
all adults with diabetes in the region live in urban areas. 
More than 1 in 4 of them were not aware they had the 
disease. It was estimated that there are 50% of people 
with undiagnosed diabetes in Indonesia. Despite being 
largely preventable, type 2 diabetes (T2DM) accounts 
for more than 90% of all diabetes cases (Soelistijo et al., 
2015). 
In 2010, American Diabetes Association (ADA) had 
recommended the use of the Hemoglobin (HbA1c) test 
to diagnose diabetes (American Diabetes Association, 
2011). HbA1c tests measure average blood glucose 
over the past two to three months. The HbA1c test is 
being used for diagnosis of T2DM and prediabetes. 
A normal HbA1c level is 5.6 percent or below and a 
level of 5.7 to 6.4 percent indicates prediabetes, while 
people with diabetes have an HbA1c level at 6.5 percent 
or above (American Diabetes Association, 2010; The 
International Expert Committee, 2009).
T2DM is associated with modifiable lifestyle risk 
factors. Smoking had raised levels of HbA1 in smokers 
which had been known as the factor causing T2DM. 
Smokers are 30-40% more likely to develop T2DM than 
nonsmokers (Nilsson et al., 2004; Vlassopoulos et al., 
2013; Xie et al., 2009). Nicotine, the main compound 
of cigarettes that causes addiction, had been proposed 
to be involved in the development of T2DM (Bajaj, 
2012; Borowitz & Isom, 2008; Xie et al., 2009). It had 
been proven that nicotine to be a risk factor for insulin 
resistance and also induced apoptosis of beta cells which 
caused decreasing insulin in blood and eventually could 
lead to higher blood glucose levels (Bergman et al., 
2012; Houston et al., 2006; Willi et al., 2007; Xu et al., 
2012).
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Nicotine is primarily metabolized in the liver by 
cytochrome P450 enzymes (CYP2A6). CYP2A6 shows 
great interindividual and interethnic variations in its 
expression levels and conversion activities, which are 
mainly attributed to CYP2A6 genetic polymorphisms. 
Genetic variation in the CYP2A6 gene could increase or 
decrease enzyme activity through altering the protein’s 
expression level or its structure and function (Hukkanen 
et al., 2005). The CYP2A6*1, a common CYP2A6 allele, 
was considered as fast metabolizer, while any other 
alleles, CYP2A6*4 and CYP2A6*9, were associated 
with slower metabolizers (Raunio & Rahnasto-Rilla, 
2012). According to Liu et al. (2011), heavy smoking 
may increase the risk of T2DM-particularly in smokers 
with CYP2A6 poor metabolizer genotypes.
This study was the first one of its kinds conducted in 
Indonesia which aimed to find out the relations between 
genetic polymorphisms, primarily CYP2A6*4 and 
CYP2A6*9 alleles, and hemoglobin among Javanese 
Indonesian smokers. By knowing these predictive 
relationships that show us how prediabetes occurs, we 
hopefully can strive for an appropriate and adequate 
prevention. Besides, we can also determine the needed 
screening data, to detect prediabetes early before it 
develops to become diabetes. This research was also 
expected to support government programs to reduce the 
number of smokers in Indonesia.
METHODS
The study was performed from August 2016 to July 
2017 using a cross-sectional design and was performed 
in 33 healthy male participants as they were not taking 
any medications. The participants were recruited from 
Sanata Dharma University’s employees which had 
three or more Javanese grandparents. Participants were 
20 to 45 years of age and were defined as a current 
regular smoker, who smoked at least one cigarette 
per day and smoked more than 100 cigarettes during 
his lifetime at the time of interview. According to the 
number of cigarettes smoked per day, participants were 
classified as light smokers (cigarettes a day/CPD < 10), 
moderate smokers (CPD 11-20) and heavy smokers 
(CPD > 20). They had been given informed consent 
sheet prior to participating in this study. Original ethical 
approval for the Laboratory Research was granted 
by the Ethics Committees of Medical Research Duta 
Wacana University No. 424/C.16/FK/2017 (Yogyakarta, 
Indonesia).
Blood samples were collected from a cubital vein just 
before genotyping of CYP2A6 and HbA1c analysis. 
Genomic DNA was prepared using Ron’s Blood and 
Cell DNA Mini Kit (Bioron-GmbH). The genotyping 
of CYP2A6*1, CYP2A6*4 and CYP2A6*9 alleles was 
previously assessed using primer-specific Polymerase 
Chain Reaction in our laboratory (Patramurti et al., 
2015; Patramurti, 2017). The primer forward: 2A6-B6 
(3’-CCT CAT CAC ACA CAA CTT CCT C-5’) and 
primer reverse: 2A6-UTRAS1 (5’-TGT AAA ATG 
GGC ATG AAC GCC C-3’) were used to identify allele 
CYP2A6*1 and CYP2A6*4, while the other primer 
(5’-GATTCCTCTCCCCTGGAAC-3’ (primer forward) 
and 5’-GGCTGGGGTGGTTTGCCTTT A-3’ (primer 
reverse) were used to identify allele CYP2A6*9. A 
total HbA1c analysis was performed by NORUDIA® N 
HbA1c in the Clinical Pathology Laboratory, Bethesda 
Hospital Yogyakarta using the Architect 600 instrument, 
which was calibrated using Diabetes Control and 
Complications Trial (DCCT) standards with coefficient 
of variation < 2.5%.
To describe the study population, we used Microsoft 
Excel 2016 in which we calculated the mean and standard 
of deviation of each continuous quantitative variable and 
the percentage for the genes. The qualitative analysis was 
used to illustrate the effect of CPY2A6 polymorphism, 
CYP2A6*1, CYP2A6*4 and CYP2A6*9 alleles, on 
HbA1c levels.
RESULTS AND DISCUSSION
Various studies reported the associations between 
smoking and CYP2A6 genotypes in the development 
of some cancer (Boffetta, 2008; Hecht, 2012; Mallery 
et al., 2014; Shields, 2002). Other studies suggested 
that smokers with defective CYP2A6 alleles are at a 
higher risk of developing T2DM (Liu et al., 2011). 
Here, we evaluated the influence of CYP2A6 genotypes 
on T2DM in Javanese Indonesian smokers based on a 
cross-sectional study, after controlling for age, gender, 
and family history of diabetes. 
There were 33 male Javanese Indonesian smokers 
participating in this study. The average of the 
participants’ age was 34.3 ± 9.3 years. Three alleles were 
identified using a PCR method among the participants, 
they were CYP2A6*1 (an active allele), CYP2A6*4 and 
CYP2A6*9. The *4 and *9 alleles are more common 
allele in Asian populations than in people of European 
ancestry. CYP2A6*4 allele is a gene deletion, leading 
for most poor metabolizers in Asians (Nakajima et al., 
2004; Yusof & Gan, 2009).  CYP2A6*9 allele is a single 
nucleotide polymorphisms (SNPs) which has a −48T to 
G nucleotide substitution in the TATA box (a sequence of 
DNA found in the core promoter region of genes) of the 
5′-flanking region of the CYP2A6, which is in the TATA 
box of the CYP2A6 promoter region. The substitution 
decreases CYP2A6 mRNA expression and subsequently 
lowers enzyme activity (Pitarque, 2001). 
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According to genotype analysis, smokers were classified 
as normal metabolizer (100% CYP2A6 activity), 
intermediate metabolizer (individuals hypothesized to 
have approximately 75% of normal activity), and slow 
metabolizer (individuals hypothesized to have 50% or 
less of the normal activity). Smokers who did not have 
any copies of CYP2A6*4 or CYP2A6*9 were classified 
as ‘normal metabolizer’ (i.e. *1/*1). Smokers who had 
only CYP2A6*9 allele were classified as ‘intermediate 
metabolizers’ (e.g. *1/*9). The ‘slow metabolizer’ group 
refers to smokers who had either CYP2A6*4 allele or 
two CYP2A6*9 alleles (e.g. *1/*4 or *9/*9) and the 
‘poor metabolizers’ were indicated as smokers who 
had either CYP2A6*4 and CYP2A6*9 allele or two 
CYP2A6*4 alleles (e.g. *9/*4, or *4/*4) (Mwenifumbo 
et al., 2008; Mwenifumbo et al., 2007; Schoedel et al., 
2004). 
In the present study, we found that all of the 33 
participants involved in the study had heterozygous 
alleles and none of the participant had homozygous 
CYP2A6*1. There are 93.9% participant had CYP2A6 
* 1/*4 genotype and 6.1% had CYP2A6 * 1/*4/*9 
genotype (Table 1). Based on this result, all participants 
were identified as slow metabolizers.  According to the 
number of cigarettes per day, participants were classified 
into three levels, light smokers (CPD < 10), moderate 
smokers (CPD 11-20) and heavy smokers (CPD > 
20). The participants involved in this study were only 
classified as light smokers (17) and moderate smokers 
(15). None of the participants were classified as heavy 
smokers, so this study was in line with numerous studies 
that had reported smokers who carry reduced activity or 
null CYP2A6 alleles do smoke less (Ando et al., 2003; 
Fujieda et al., 2004; Liu, David, et al., 2011; Minematsu 
et al., 2006; Schoedel et al., 2004; Rao et al., 2000). 
About 70 to 80% of inhaled nicotine was converted 
to cotinine by the CYP2A6 enzyme; cotinine was 
further oxidized into trans-3-hydroxycotinine by this 
enzyme and all three compounds were excreted in urine 
(Hukkanen et al., 2005) (Figure 1). 
Metabolism of nicotine had associations for addiction 
Figure 1. Primary metabolism pathway of nicotine 
facilitated by CYP2A6
Table 1. Allele frequencies of CYP2A6*1, CYP2A6*4, CYP2A6*9
and genotype among Javanese smokers
Allele
Frequency (n=68)
Total
CPD < 10 (n=20) CPD 11-20 (n=13)
CYP2A6*1
CYP2A6*4 
CYP2A6*9
29.4% (20)
29.4% (20)
0
19.1% (13)
19.1% (13)
3 % (2)
48.5% (33)
48.5% (33)
3% (2)
Genotipe Frequency (n=33) Total
CYP2A6*1/*1
CYP2A6*1/*4
CYP2A6*1/*9
CYP2A6*1/*4/*9
CYP2A6*4/*4
CYP2A6*4/*9
CYP2A6*9/*9
0% (0)
60.6% (20)
0% (0)
0% (0)
0% (0)
0% (0)
0% (0)
0% (0)
33.3% (11)
0% (0)
6.1% (2)
0% (0)
0% (0)
0% (0)
0% (0)
93.9% (31)
0% (0)
6.1% (2)
0% (0)
0% (0)
0% (0)
and would have impact on risk of T2DM in smokers. 
Variation in the CYP2A6 gene could decrease the rate 
of nicotine metabolic-inactivation, therefore smokers 
with slow or poor metabolizer genotypes, whose CPD 
was more than 20, were more likely to saturate this 
metabolism pathway, resulting to higher nicotine plasma 
levels. These slow metabolizers would then be more 
likely to develop T2DM due to their higher level of 
nicotine in blood (Bajaj, 2012; Borowitz & Isom, 2008; 
Xie et al., 2009). Some studies suggested that nicotine 
either could have toxic effect on the pancreatic beta 
cells, or causing insulin resistance that leading to high 
risk of T2DM (Bajaj, 2012; Bergman et al., 2012; Xu 
et al., 2012). Some other studies reported that smoking 
would increase the HbA1c level (Nilsson et al., 2004; 
Vlassopoulos et al., 2013). 
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Results of our study showed that HbA1c levels among 
participants were ranging from 4,83-7,16% with an 
average of 5.27 and SD of 0.427. Based on our results, 
almost all participants had a normal HbA1c level, four 
participants were on prediabetes condition and only 
one participant was identified suffering diabetes. The 
prediabetes condition mean that smokers might have a 
higher chance of getting diabetes, depending on level 
of hemoglobin A1c and presence of other risk factors, 
such as obesity and family history (American Diabetes 
Association, 2010). 
None of the participants involved in this study was 
classified as heavy smoker and all of them were identified 
as slow metabolizers. This result was consistent with 
Liu et al. (2011) which demonstrated that the risk of 
T2DM was higher in heavy smokers who have slow 
or poor metabolizer genotypes rather than in light or 
intermediate smokers with slow or normal metabolizers. 
The participants who had HbA1c level more than 5.7% 
(prediabetes and diabetic conditions) were observed 
in individuals who smoke cigarettes for more than 25 
years (Figure 2). These results support other studies that 
reveal chronic smokers with slow and poor metabolizer 
genotypes would have high risk of T2DM caused by the 
pancreas exposed to greater circulating levels of nicotine 
that might contribute to apoptosis of islet β-cells and 
furthermore decreasing insulin secretion (Jyothirmayi et 
al., 2013). 
Any other compounds, pre-carcinogens, found in tobacco 
smoke, such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK), 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanol (NNAL); N-nitrosodiethylamine (NDEA), 
could be activated to carcinogens by CYP2A6 in liver 
or CYP2E1 expressed in pancreatic islets (Anttila et 
al., 2011; Brown et al., 2007; Hecht, 2003; Wang et al., 
2012). Therefore, smokers with CYP2A6 slow or poor 
metabolizing genotype, the hepatic first-pass clearance of 
these compounds might be decreased lead to increasing 
systemic levels of these pre-carcinogens and more 
exposure of other organs, such as pancreas. Ultimately, 
the higher levels of nitrosamines in pancreatic islet cells 
will cause metabolic activation by CYP2E1, which 
lead to pancreatic inflammation and apoptosis of islet 
β-cells, followed by the reducing insulin secretion and 
consequently the increasing risk of incident T2DM.
Most previous experimental and clinical studies described 
that nicotine decreased insulin sensitivity. Bergman et al. 
(2009) revealed that chronic cigarette smokers were less 
insulin sensitive compared with control subjects that did 
not smoke. Furthermore, Bergman et al. (2012) had found 
that nicotine could increase mTOR/p70S6 K activity in 
cultured L6 myotubes in relation with increased IRS-1 
Ser 636 phosphorylation and induced insulin resistance 
in skeletal muscle which subsequently reduced insulin-
stimulated glucose uptake. 
This study supports the hypothesis that the blood 
glucose levels might be increased in smokers, who may 
have high risk to diabetes mellitus, if smoking is not 
controlled. Furthermore, our study also supports many 
previous studies that CYP2A6 polymorphism, primarily 
caused by defective alleles (*4 and *9), would be a 
factor of high risk on T2DM. These findings suggest that 
chronic smokers whose genotype as slow metabolizer 
would enhance the development of T2DM. It induces the 
reduction of insulin secretion caused by the toxic effect 
of nicotine or nitrosamine compound to the pancreas 
as well as the occurrence of insulin resistance. Finally, 
the results expand the understanding to the possibility 
effects of cigarette smoking on T2DM. It may have 
major public health consequences for tobacco control 
Figure 2. Distribution of HbA1c levels among Javanese Indonesian smokers 
based on smoking duration (year)
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and efforts to prevent the development of diabetes in 
Indonesia, especially to the Javanese smokers.
CONCLUSION 
Diabetes mellitus is one of serious problem on public 
health that many people are unaware of suffering this 
disease. Diabetes in Indonesia, mostly T2DM caused 
by lifestyle, is growing precipitously. Smoking, another 
public health problem encountered in Indonesia, is one 
of lifestyle factors that causes diabetes. Chronic smokers, 
either light or intermediate smokers, whose genotypes 
were classified as slow and poor metabolizers, would 
have high risk of suffering T2DM.
The most important limitations of this study that other 
factors have not been investigated. They might be 
confounding to our results, for example obesity, physical 
activity, dietary factors and biochemical variation such 
as plasma nicotine levels or total urinary nicotine 
equivalents.
ACKNOWLEDGMENT
This study was supported by a grant from Research 
and Community Service Institute of Sanata Dharma 
University.
REFERENCES
Ando, M., Hamajima, N., Ariyoshi, N., Kamataki, T., 
Matsuo, K., & Ohno, Y. (2003). Association of CYP2A6 
gene deletion with cigarette smoking status in Japanese 
adults. Journal of Epidemiology /Japan Epidemiological 
Association, 13(3), 176-181
Anttila, S., Raunio, H., & Hakkola, J. (2011). Cytochrome 
P450-Mediated Pulmonary Metabolism of Carcinogens. 
American Journal of Respiratory Cell and Molecular 
Biology, 44(5), 583-590
American Diabetes Association. (2010). Diagnosis and 
Classification of Diabetes Mellitus. Diabetes Care, 33
American Diabetes Association. (2011). Executive 
Summary: Standards of Medical Care in Diabetes-2011. 
Diabetes Care, 34(Supplement 1), S4-S10
Bajaj, M. (2012). Nicotine and Insulin Resistance: When 
the Smoke Clears. Diabetes, 61(12), 3078-3080
Bergman, B. C., Perreault, L., Hunerdosse, D., Kerege, 
A., Playdon, M., Samek, A. M., & Eckel, R. H. (2012). 
Novel and Reversible Mechanisms of Smoking-Induced 
Insulin Resistance in Humans. Diabetes, 61(12), 3156-
3166
Bergman, B. C., Perreault, L., Hunerdosse, D. M., 
Koehler, M. C., Samek, A. M., & Eckel, R. H. (2009). 
Intramuscular lipid metabolism in the insulin resistance 
of smoking. Diabetes, 58(10), 2220-2227
Boffetta, P. (2008). Tobacco smoking and risk of 
bladder cancer. Scandinavian Journal of Urology and 
Nephrology. Supplementum, (218), 45-54
Borowitz, J. L., & Isom, G. E. (2008). Nicotine and Type 
2 Diabetes. Toxicological Sciences, 103(2), 225-227
Brown, P. J., Bedard, L. L., Reid, K. R., Petsikas, D., & 
Massey, T. E. (2007). Analysis of CYP2A contributions 
to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone in human peripheral lung microsomes. Drug 
Metabolism and Disposition: The Biological Fate of 
Chemicals, 35(11), 2086-2094
 
Buell, C., Kermah, D., & Davidson, M. B. (2007). 
Utility of A1C for diabetes screening in the 1999 2004 
NHANES population. Diabetes Care, 30(9), 2233-2235 
Fujieda, M., Yamazaki, H., Saito, T., Kiyotani, K., 
Gyamfi, M. A., Sakurai, M., … Kamataki, T. (2004). 
Evaluation of CYP2A6 genetic polymorphisms as 
determinants of smoking behavior and tobacco-
related lung cancer risk in male Japanese smokers. 
Carcinogenesis, 25(12), 2451-2458 
Hecht, S. S. (2003). Tobacco carcinogens, their 
biomarkers and tobacco-induced cancer. Nature 
Reviews. Cancer, 3(10), 733-744 
Hecht, S. S. (2012). Lung carcinogenesis by tobacco 
smoke. International Journal of Cancer. Journal 
International Du Cancer, 131(12), 2724-2732 
Houston, T. K., Person, S. D., Pletcher, M. J., Liu, K., 
Iribarren, C., & Kiefe, C. I. (2006). Active and passive 
smoking and development of glucose intolerance among 
young adults in a prospective cohort: CARDIA study. 
BMJ, 332(7549), 1064-1069 
Hukkanen, J., Jacob, P., & Benowitz, N. L. (2005). 
Metabolism and disposition kinetics of nicotine. 
Pharmacological Reviews, 57(1), 79-115 
International Diabetes Federation (2017). IDF Diabetes 
Atlas Eighth edition 2017. IDF
Jyothirmayi, B., Kaviarasi, S., & William, E. (2013). 
Study of glycated hemoglobin in chronic cigarette 
smokers. International Journal of Pharmaceutical and 
Clinical Research, 5(1), 4-6
Patramurti, et al.
E-ISSN 2477-0612
87
Liu, T., Chen, W.-Q., David, S. P., Tyndale, R. F., Wang, 
H., Chen, Y.-M., … Ling, W.-H. (2011). Interaction 
between heavy smoking and CYP2A6 genotypes on type 
2 diabetes and its possible pathways. European Journal 
of Endocrinology/European Federation of Endocrine 
Societies, 165(6), 961-967
Liu, T., David, S. P., Tyndale, R. F., Wang, H., Zhou, 
Q., Ding, P., … Chen, W.-Q. (2011). Associations of 
CYP2A6 genotype with smoking behaviors in southern 
China. Addiction (Abingdon, England), 106(5), 985-994 
Mallery, S. R., Tong, M., Michaels, G. C., Kiyani, A. R., 
& Hecht, S. S. (2014). Clinical and Biochemical Studies 
Support Smokeless Tobacco’s Carcinogenic Potential in 
the Human Oral Cavity. Cancer Prevention Research, 
7(1), 23-32 
Minematsu, N., Nakamura, H., Furuuchi, M., Nakajima, 
T., Takahashi, S., Tateno, H., & Ishizaka, A. (2006). 
Limitation of cigarette consumption by CYP2A6*4, 
*7 and *9 polymorphisms. The European Respiratory 
Journal, 27(2), 289-292 
Mwenifumbo, J. C., Al Koudsi, N., Ho, M. K., Zhou, Q., 
Hoffmann, E. B., Sellers, E. M., & Tyndale, R. F. (2008). 
Novel and established CYP2A6 alleles impair in vivo 
nicotine metabolism in a population of Black African 
descent. Human Mutation, 29(5), 679-688
 
Mwenifumbo, J. C., Sellers, E. M., & Tyndale, R. F. 
(2007). Nicotine metabolism and CYP2A6 activity in a 
population of black African descent: Impact of gender 
and light smoking. Drug and Alcohol Dependence, 
89(1), 24-33
 
Nakajima, M., Yoshida, R., Fukami, T., McLeod, H. 
L., & Yokoi, T. (2004). Novel human CYP2A6 alleles 
confound gene deletion analysis. FEBS Letters, 569(1-
3), 75-81
 
Nilsson, P. M., Gudbjörnsdottir, S., Eliasson, B., & 
Cederholm, J. (2004). Smoking is associated with 
increased HbA1c values and microalbuminuria in 
patients with diabetes-data from the National Diabetes 
Register in Sweden. Diabetes & Metabolism, 30(3), 
261-268
 
Patramurti, C. (2017). Studi Genotipe Sitokrom P450 
2A6 Alel CYP2A6 *4 dan CYP2A6 *9 pada Subyek 
Uji Perokok Suku Jawa Indonesia (Genotyping Study of 
Cytochrome P450 2A6 Alel CYP2A6 *1 and CYP2A6 
*9 among Javanese Indonesian Smokers), 15(1), 50-56
Patramurti, C., Nurrochmad, A., Martono, S., Science, 
P., Mada, G., & Chemistry, P. (2015). Poymorphism of 
Cytochrome P450 2A6 (CYP2A6 *1 AND CYP2A6 *4) 
among Javaneses Indonesia Smoker and Non Smoker, 
26(1), 11-19
 
Pitarque, M., Richter, O., Oke, B., Berkkan, H., 
Oscarson, M., and Ingelman- Sundberg, M. (2001). 
Identification of a Single Nucleotide Polymorphism 
in the TATA Box of the CYP2A6 Gene: Impairment 
of Its Promoter Activity, Biochemical and Biophysical 
Research Communications, 284, 455-460
Rao, Y., Hoffmann, E., Zia, M., Bodin, L., Zeman, M., 
Sellers, E. M., & Tyndale, R. F. (2000). Duplications 
and defects in the CYP2A6 gene: identification, 
genotyping, and in vivo effects on smoking. Molecular 
Pharmacology, 58(4), 747-755
Raunio, H., & Rahnasto-Rilla, M. (2012). CYP2A6: 
genetics, structure, regulation, and function. Drug 
Metabolism and Drug Interactions, 27(2), 73-88
 
Schoedel, K. a, Hoffmann, E. B., Rao, Y., Sellers, E. M., 
& Tyndale, R. F. (2004). Ethnic variation in CYP2A6 
and association of genetically slow nicotine metabolism 
and smoking in adult Caucasians. Pharmacogenetics, 
14(9), 615-626
 
Shields, P. G. (2002). Molecular epidemiology of 
smoking and lung cancer. Oncogene, 21(45), 6870-6876 
Soelistijo, S.A; Novida, H.; Rudijanto, A.; Soewondo, 
P.; Suastika, K.; Manaf, A. et al. (2015). Konsensus 
Pengendalian dan Pencegahan Diabetes Melitus Tipe 2 
di Indonesia 2015. Perkeni
The International Expert Committee. (2009). 
International Expert Committee Report on the Role of 
the A1C Assay in the Diagnosis. Diabetes Care, 32(7)
 
Vlassopoulos, A., Lean, M. E., & Combet, E. (2013). 
Influence of smoking and diet on glycated haemoglobin 
and ‘pre-diabetes’ categorisation: a cross-sectional 
analysis. BMC Public Health, 13, 1013
 
Wang, J., Xu, Y., Li, J., Sun, X., Wang, L.-P., & Ji, W.-Y. 
(2012). The tobacco-specific carcinogen NNK induces 
DNA methyltransferase 1 accumulation in laryngeal 
carcinoma. Oral Oncology, 48(6), 541-546
 
Willi, C., Bodenmann, P., Ghali, W. A., Faris, P. D., & 
Cornuz, J. (2007). Active smoking and the risk of type 2 
diabetes: a systematic review and meta-analysis. JAMA, 
298(22), 2654-2664
 
Genetic Polymorphism of Cytochrome Pharm Sci Res, Vol 6 No 2, 2019
E-ISSN 2477-0612
88 Pharm Sci Res, Vol 6 No 2, 2019
Xie, X., Liu, Q., Wu, J., & Wakui, M. (2009). Impact of 
cigarette smoking in type 2 diabetes development. Acta 
Pharmacologica Sinica, 30(6), 784-787
Xu, T., Guo, L., Wang, P., Song, J., Le, Y., Viollet, B., & 
Miao, C. (2012). Chronic Exposure to Nicotine Enhances 
Insulin Sensitivity through a 7 Nicotinic Acetylcholine 
Receptor-STAT3 Pathway, 7(12), 1-10
Yusof, W., & Gan, S. H. (2009). High prevalence of 
CYP2A6*4 and CYP2A6*9 alleles detected among 
a Malaysian population. Clinica Chimica Acta; 
International Journal of Clinical Chemistry, 403(1–2), 
105-109. 
Patramurti, et al.
